About PHP Biotech
Founded to treat cancers that still outrun medicine
Our journey began with a simple but ambitious goal: better treatment options for people facing the most aggressive and difficult-to-treat cancers. PHP53-nb is the first expression of that goal — not the last.
Our story
PHP Biotech is a US-based, privately held company founded in 2020 by innovative healthcare entrepreneurs and powered by a world-class scientific and research team plus global CROs and CDMOs. Working with leading laboratories, the team discovered two key innovations — the p53-reactivating peptide 3-NAntC and the humanized camelid nanobody platform GEN01-AD — which together form PHP53-nb.
Getting here took time: more than five years of peptide screening, then two years developing and scaling GEN01-AD. The result has shown encouraging results in TNBC and other aggressive types, including pancreatic cancer, and opens combination and multi-specific approaches beyond a single therapy.
Headquarters: 550 Reserve St., Ste. 190, Southlake, TX 76092. View the company bibliography.
How we got here
Years 1–5
Peptide discovery & screening
More than five years screening and refining p53-reactivating peptide candidates, culminating in 3-NAntC.
Years 6–7
GEN01-AD platform
Two years designing and scaling a humanized camelid nanobody delivery platform for stable, linker-free peptide delivery.
Year 8
PHP53-nb emerges
The lead candidate demonstrates encouraging preclinical results in TNBC and other aggressive cancers, including pancreatic models.
2026
Preclinical studies
Planned completion of the core preclinical package, including efficacy, mechanism, toxicity, characterization, and biodistribution.
2027
Clinical trials
Anticipated start of Phase I first-in-human studies, subject to regulatory review.
Leadership
Oncology, operations, finance, and scientific research united around a single clinical goal.
Robert Gahagen
Chief Executive Officer
The operating system behind a first-in-class nanobody
Eduardo Motti, MD
Chief Operating Officer
Five hundred trials, then a nanobody
3 publications
João Marcelo Carucci
Chief Financial Officer
One company. Two assets. A single runway.
Patrícia Bezerra, PhD
Head of Research & Development
The scientist who made 3-NAntC small enough to matter
5 publications · 1 patent · ORCID
Executive committee
Strategic oversight of operations, partnerships, and long-term vision.
Moacyr Bighetti
Founder & Executive Committee
The patent is the origin story
1 patent
Oswaldo Bighetti Neto
Executive Committee Member
The contracts that have to exist before a nanobody can move
Eduardo Braun, MD
Executive Committee Member
Still seeing patients. Still reading genomes.
1 publication
Paulo Nigro
Executive Committee Member
Tetra Pak. Aché. A cancer hospital. Then a nanobody.
Advisory board
Clinical, scientific, and commercial expertise from bench toward clinic.
Antonio Carlos Buzaid, MD
Advisory Board Member
He helped rewrite how melanoma is staged. Then he came home.
7 publications
Fabio A. Jung, MD
Advisory Board Member
MD Anderson on one side. Wharton on the other.
Jorge Brasil, MD
Advisory Board Member
Evidence has to survive contact with a payer
Kleber Miranda
Advisory Board Member
Twenty-one countries is a distribution problem